
Biotechnology firms are increasingly turning to innovative combination therapies to tackle hard-to-treat cancers, with promising results sparking investor interest. AIM ImmunoTech Inc. (NYSE:AIM) is the latest to capture attention, as its stock soars following a promising mid-year update from the DURIPANC Phase 2 study.
The study is evaluating Ampligen (rintatolimod) in combination with AstraZeneca Plc’s (NASDAQ:AZN) anti-PD-L1 immune checkpoint inhibitor, Imfinzi (durvalumab), in metastatic pancreatic cancer patients with stable disease following FOLFIRINOX treatment.